OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 22.090 |
| Open | 21.970 |
| Bid | 22.250 x 1200 |
| Ask | 22.700 x 800 |
| Day's Range | 21.825 - 22.712 |
| 52 Week Range | 12.750 - 48.000 |
| Volume | 14,072 |
| Avg. Volume | 49,032 |
| Market Cap | 63.651M |
| Beta | -0.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.064 |
| Earnings Date | Mar 14, 2018 - Mar 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.00 |
- Simply Wall St.•6 days ago
How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?
If you own shares in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
- GlobeNewswire•10 days ago
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, and Consort Medical plc (“Consort”) (CSRT.L), a leading contract development and manufacturing organization, today announced a development and manufacturing agreement for Opiant’s OPNT003 (intranasal nalmefene), a potent, long-acting opioid antagonist for the treatment of opioid overdose. Under this agreement, Aesica and Bespak, wholly-owned subsidiaries of Consort, will work with Opiant to produce a pre-filled delivery nasal spray with nalmefene.
- GlobeNewswire•16 days ago
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
SANTA MONICA, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for the treatment of Bulimia Nervosa. The Company expects to report top-line data from this trial in the first quarter of 2019.
- ACCESSWIRE•21 days ago
Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. receives tiered royalties. Shares of Sophiris Bio also saw big gains after announcing updates on a phase 2b Localized Prostate Cancer Trial.
- Zacks Small Cap Research•22 days ago
OPNT: Adapt Pharma® Acquired for $650 Million…
On August 28, 2018, Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million with the potential for another $100 million in sales-based milestones through 2022. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. (OPNT) receives tiered royalties. Emergent also announced that projected 2019 revenues for NARCAN® Nasal Spray will be $200-$220 million, net of royalty payments to Opiant.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of Influence
NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capital ...
- Zacks Small Cap Research•last month
OPNT: Increasing Royalties from NARCAN® Nasal Spray…
Earlier in 2018, Opiant (OPNT) announced the receipt of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) to fund the development of OPNT003, a long-lasting opioid antagonist for the treatment of opioid overdose. Based on its favorable pharmacokinetic profile, we believe OPNT003 could become a novel opioid overdose treatment, particularly for overdoses caused by synthetic opioids such as fentanyl and its derivatives. The following chart shows the number of overdose deaths in the U.S. from certain drugs, with the rapid rise in deaths from synthetic opioids just since 2013 particularly striking.
- GlobeNewswire•last month
Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Aug. 09, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today reported financial results ...
- ACCESSWIRE•last month
Opiant Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern ...
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9
SANTA MONICA, Calif., Aug. 02, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it will ...
- GlobeNewswire•3 months ago
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that it has received the first tranche of $500,000 from the previously awarded grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. “We are pleased to receive these initial funds from the NIH and are preparing to conduct key formulation studies of OPNT003,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Following completion of the formulation studies, we intend to initiate a confirmatory pharmacokinetic study which would position us to potentially submit an NDA for OPNT003 and intranasal delivery device combination, in 2020. Based on the data generated to date, we believe OPNT003 will have a substantially longer half-life than naloxone, which has been previously approved by the FDA for treating suspected or confirmed opioid overdose.
- Zacks Small Cap Research•4 months ago
OPNT: KOL Event Highlights Medications for Addictions and Related Disorders
Dr. Comer is a Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons at Columbia University. Dr. Comer began her talk with an overview of the epidemiology of the opioid epidemic. The following graphic shows the startling increase in drug overdose deaths from 1999 to 2016.
- ACCESSWIRE•5 months ago
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT) ("Opiant"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPNT as the Company's latest news hit the wire. On April 18, 2018, the Company, which is a specialty pharmaceutical organization developing pharmacological treatments for addictions, declared that the National Institutes of Health's National Institute on Drug Abuse (NIDA) has granted it an award of approximately $7.4 million for the development of OPNT003 (intranasal nalmefene) for opioid overdose.
- ACCESSWIRE•6 months ago
Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates
Stock Monitor: Opiant Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free earnings report on HubSpot, Inc. (NYSE: HUBS ). If you want ...
- Zacks Small Cap Research•6 months ago
OPNT: Opiant Developing New Opioid Overdose Treatment
As part of the solution to the problem, the CDC recommends that the federal government “improve access to…overdose-reversing drugs, such as naloxone” and that health departments “increase naloxone distribution to first responders, family and friends, and other community members in affected areas” (CDC). While not a treatment for opioid dependence, health authorities believe that easy access to naloxone is an essential component of battling the ongoing opioid crisis due to its effectiveness in preventing overdose deaths. On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment.
- Reuters•6 months ago
Trump says he is working to lower prescription drug prices
President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. "If you compare our drug prices to other countries in the world, in some cases it's many times higher for the exact same pill or whatever it is, in the exact same package made in the exact same plant," Trump said. Trump made the remarks during a speech in Manchester, New Hampshire that focused on the administration's efforts to battle the nation's opioid addiction crisis.
- Reuters•6 months ago
As U.S. opioid crisis grows, Trump calls for death penalty for dealers
President Donald Trump spelled out in new detail several steps he favors to fight a U.S. epidemic of opioid abuse, including the execution of drug dealers, a proposal that has gained little support from drug abuse and judicial experts. At an event in Manchester, New Hampshire, Trump unveiled an anti-opioid abuse plan, including his death penalty recommendation, new funding for other initiatives and stiffer sentencing laws for drug dealers.
